Cognitive health protocols using peptides for memory, neuroplasticity, focus, and cognitive decline prevention. The peptide revolution promises to rewire your brain, but your immune system might have other plans. This hub maps memory (from Dihexa's synaptogenic hammer to Cerebrolysin's clinical track record), focus and ADHD (what the literature actually supports vs what forums claim), and anxiety (synthetic glyprolines engineered to modulate the HPA axis). Two sister peptides from the same Cold War lab anchor the pharmacology: Selank calms the emotional floor, Semax raises the cognitive ceiling.
From Dihexa's synaptogenic hammer to Cerebrolysin's clinical track record — five realities of the peptide cognition frontier, and the regulatory minefield around them.
A three-amino-acid peptide that bypasses the blood-brain barrier, enters the nucleus, and directly modulates gene expression for neuroprotection.
A tuftsin-derived heptapeptide that delivers benzodiazepine-level anxiety relief without sedation, dependence, or cognitive fog — while simultaneously boosting immune defence.
An ACTH-derived heptapeptide that upregulates BDNF, modulates the Default Mode Network, and delivers 20-24 hours of neuroprotection per dose — without a single hormonal side effect.
Cerebrolysin is a porcine-brain peptide mixture sold as a master key for brain repair. It has decades of human trials, approval in 50+ countries, no FDA approval, and a Cochrane safety signal that complicates the story.
DSIP was named for inducing delta sleep, but independent labs failed to replicate that in humans, no one has found its receptor or gene, and its best human stress trial found zero effect. Fascinating biology, unproven clinically.